Department of Cardiology II - Electrophysiology, University Hospital Muenster, Albert-Schweitzer-Campus 1, Muenster, Germany.
Department of Cardiology II - Electrophysiology, University Hospital Muenster, Albert-Schweitzer-Campus 1, Muenster, Germany.
J Cardiol. 2022 Oct;80(4):298-302. doi: 10.1016/j.jjcc.2022.04.010. Epub 2022 May 16.
Recent studies suggest cardiac involvement with an increased incidence of arrhythmias in the setting of coronavirus disease 2019 (COVID-19). The aim of this study was to evaluate the risk of potentially lethal arrhythmias and atrial fibrillation in patients with COVID-19-induced acute respiratory distress syndrome (ARDS) and to elicit possible predictors of arrhythmia occurrence.
A total of 107 patients (82 male, mean age 60 ± 12 years, median body mass index 28 kg/m) treated for COVID-19-induced ARDS in a large tertiary university hospital intensive care unit between March 2020 and February 2021 were retrospectively analyzed. Eighty-four patients (79%) had at least moderate ARDS, 88 patients (83%) were mechanically ventilated, 35 patients (33%) received vvECMO. Forty-three patients (40%) died during their hospital stay. Twelve patients (11%) showed potentially lethal arrhythmias (six ventricular tachycardia, six significant bradycardia). Atrial fibrillation occurred in 27 patients (25%). In a multivariate logistic regression analysis, duration of hospitalization was associated with the occurrence of potentially lethal arrhythmias (p = 0.006). There was no association between possible predictive factors and the occurrence of atrial fibrillation. Invasive ventilation, antipsychotics, and the QT interval were independently associated with acute in-hospital mortality, but this was not arrhythmia-driven as there was no association between the occurrence of arrhythmias and mortality.
In this relatively young population with COVID-19-induced ARDS, the incidence of potentially lethal arrhythmias was low. While overall mortality was high in these severely affected patients, cardiac involvement and arrhythmia occurrence was not a significant driver of mortality.
最近的研究表明,在 2019 年冠状病毒病(COVID-19)背景下,心脏受累导致心律失常的发生率增加。本研究旨在评估 COVID-19 引起的急性呼吸窘迫综合征(ARDS)患者发生潜在致命性心律失常和心房颤动的风险,并找出心律失常发生的可能预测因素。
对 2020 年 3 月至 2021 年 2 月期间在一家大型三级大学医院重症监护病房接受 COVID-19 诱导的 ARDS 治疗的 107 例患者(82 例男性,平均年龄 60±12 岁,中位数体重指数 28kg/m²)进行回顾性分析。84 例(79%)患者至少存在中度 ARDS,88 例(83%)患者接受机械通气,35 例(33%)患者接受静脉-静脉体外膜肺氧合(vvECMO)。43 例(40%)患者在住院期间死亡。12 例(11%)患者出现潜在致命性心律失常(6 例室性心动过速,6 例严重心动过缓)。心房颤动发生在 27 例患者(25%)中。在多变量逻辑回归分析中,住院时间与潜在致命性心律失常的发生相关(p=0.006)。在可能的预测因素中,没有与心房颤动发生相关的因素。有创通气、抗精神病药物和 QT 间期与急性院内死亡率独立相关,但这不是心律失常驱动的,因为心律失常的发生与死亡率之间没有关联。
在 COVID-19 诱导的 ARDS 患者中,这是一个相对年轻的人群,潜在致命性心律失常的发生率较低。尽管这些严重受影响的患者的总体死亡率较高,但心脏受累和心律失常的发生并不是死亡率的主要驱动因素。